Biotecnol Limited

In Dec 2018, Biotecnol divested from its immuno-oncology pipeline and respective technologies (including Tb535H, and Trisoma). Chiome will continue research and clinical development for Tb535H. In addition, Chiome will also continue generating new immune-oncology products using Biotecnols Trisoma technology. Financial details were not disclosed. Biotecnol Limited, a spin-off of Biotecnol SA, a Portuguese pioneering company with a 20 year track record in development of Biologics, is an immuno-oncology company developing immune-function activating and immuno function modulation approaches using multi-specific antibody products based on its proprietary TribodyTM and Trisoma technologies. Biotecnol has devised a novel way to further expand on the...

Recombinant antibodies,t cell engaging,multispecific antibodies,oncology,and immuno-oncology

Biotecnol limited operates in the Biotechnology research industry.

Biotecnol limited's revenue is 11m - 100m

Biotecnol limited has 11 - 50 employees.